EurekAlert!

ALK mutation: A predictive biomarker for pan-cancer immunotherapy

This research, published in the Genes & Diseases journal by a team from Fujian Medical University and Sun Yat-Sen University, conducted a comprehensive bioinformatic and clinical analysis to examine ...
Medical Xpress

Researchers recommend new standard of care for families with hereditary neuroblastoma linked to ALK mutation

Researchers at Children's Hospital of Philadelphia (CHOP) highlighted the success of anaplastic lymphoma kinase (ALK) inhibition therapy in treating hereditary neuroblastoma, a rare subset of a common ...
ascopubs.org

Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High-Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study

Risks of Organ Preservation in Rectal Cancer: Data From Two International Registries on Rectal Cancer Clonal and subclonal mutations (variant allele frequency ≥5%) in ALK confer inferior prognosis for ...
Medical Xpress

Promising preclinical therapy exploits ALK protein to selectively destroy tumors while sparing healthy cells

Researchers at Children's Hospital of Philadelphia (CHOP) unveiled a novel antibody-drug conjugate (ADC) that shows striking efficacy against cancers that express the anaplastic lymphoma kinase (ALK) ...
ascopubs.org

Disparities in the prevalence of EGFR mutations and ALK rearrangements by racial-ethnic group in South Florida with a focus on Hispanic patients, 2011-2019.

Health outcomes of pembrolizumab plus chemotherapy in non-small cell lung cancer. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a full text ...
Cure Today

Datroway May Be Effective in Non-Small Cell Lung Cancer Subtypes

Datroway shows promising antitumor activity in advanced NSCLC with EGFR mutations and ALK rearrangements, achieving a 35.8% overall response rate. The treatment maintains a manageable safety profile, ...